JP2021528423A5 - - Google Patents
Info
- Publication number
- JP2021528423A5 JP2021528423A5 JP2020570938A JP2020570938A JP2021528423A5 JP 2021528423 A5 JP2021528423 A5 JP 2021528423A5 JP 2020570938 A JP2020570938 A JP 2020570938A JP 2020570938 A JP2020570938 A JP 2020570938A JP 2021528423 A5 JP2021528423 A5 JP 2021528423A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antigen
- bispecific antibody
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688251P | 2018-06-21 | 2018-06-21 | |
| US62/688,251 | 2018-06-21 | ||
| PCT/US2019/038163 WO2019246356A1 (en) | 2018-06-21 | 2019-06-20 | Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021528423A JP2021528423A (ja) | 2021-10-21 |
| JP2021528423A5 true JP2021528423A5 (https=) | 2022-06-23 |
| JP7403480B2 JP7403480B2 (ja) | 2023-12-22 |
Family
ID=67254001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570938A Active JP7403480B2 (ja) | 2018-06-21 | 2019-06-20 | 二重特異性抗ｃｄ３×ｍｕｃ１６抗体および抗ｐｄ－１抗体で癌を治療する方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11254752B2 (https=) |
| EP (2) | EP4424712A3 (https=) |
| JP (1) | JP7403480B2 (https=) |
| KR (1) | KR102870971B1 (https=) |
| CN (1) | CN112312970B (https=) |
| AU (1) | AU2019290170B2 (https=) |
| BR (1) | BR112020025476A2 (https=) |
| CA (1) | CA3103887A1 (https=) |
| CL (1) | CL2020003256A1 (https=) |
| DK (1) | DK3810281T3 (https=) |
| EA (1) | EA202190088A1 (https=) |
| ES (1) | ES2984972T3 (https=) |
| FI (1) | FI3810281T3 (https=) |
| HU (1) | HUE067985T2 (https=) |
| IL (1) | IL279251B2 (https=) |
| MA (2) | MA71708A (https=) |
| MX (2) | MX2020013905A (https=) |
| MY (1) | MY202134A (https=) |
| PH (1) | PH12020552115A1 (https=) |
| PL (1) | PL3810281T3 (https=) |
| PT (1) | PT3810281T (https=) |
| RS (1) | RS65886B1 (https=) |
| SG (1) | SG11202012137UA (https=) |
| TW (2) | TW202504917A (https=) |
| WO (1) | WO2019246356A1 (https=) |
| ZA (1) | ZA202007599B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| WO2016161010A2 (en) | 2015-03-30 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| CA3110513A1 (en) | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| IL300835A (en) * | 2020-09-02 | 2023-04-01 | Genmab As | Antibody therapy |
| AU2022214319A1 (en) | 2021-01-28 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| WO2022197907A2 (en) * | 2021-03-18 | 2022-09-22 | Memorial Sloan-Kettering Cancer Center | Methods for treating gynecologic cancer using combination therapy with anti-muc16 x cd3 multispecific antibodies and vegf inhibitors |
| EP4397320A1 (en) | 2021-08-31 | 2024-07-10 | Nihon Medi-Physics Co., Ltd. | Radioactive complex of deglycosylated antibody and radioactive pharmaceutical product |
| EP4437003A1 (en) * | 2021-11-24 | 2024-10-02 | Regeneron Pharmaceuticals, Inc. | Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies |
| US20230312718A1 (en) * | 2022-01-07 | 2023-10-05 | Regeneron Pharmaceuticals, Inc | Methods of Treating Recurrent Ovarian Cancer with Bispecific Anti-MUC16 x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies |
| JP2025504795A (ja) | 2022-01-10 | 2025-02-19 | ナンチン リーズ バイオラブス カンパニー，リミティド | 抗体及びその用途 |
| US20250195645A1 (en) * | 2022-03-16 | 2025-06-19 | Daiichi Sankyo Company, Limited | Combination of multispecific molecule and immune checkpoint inhibitor |
| EP4507790A1 (en) | 2022-04-11 | 2025-02-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| CN120857940A (zh) | 2023-02-17 | 2025-10-28 | 瑞泽恩制药公司 | 对cd3/taa双特异性抗体有反应的诱导型nk细胞 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| AU2016325630B2 (en) * | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| LT3394103T (lt) * | 2015-12-22 | 2023-09-11 | Regeneron Pharmaceuticals, Inc. | Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti |
| TWI910495B (zh) | 2016-05-13 | 2026-01-01 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| JP7066690B2 (ja) | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| MY203000A (en) * | 2016-10-14 | 2024-06-01 | Xencor Inc | Il15/il15r� heterodimeric fc-fusion proteins |
| BR112019010878A2 (pt) | 2016-11-29 | 2019-10-01 | Lindhofer Horst | combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos |
-
2019
- 2019-06-19 TW TW113114645A patent/TW202504917A/zh unknown
- 2019-06-19 TW TW108121196A patent/TWI890661B/zh active
- 2019-06-20 MA MA71708A patent/MA71708A/fr unknown
- 2019-06-20 ES ES19739472T patent/ES2984972T3/es active Active
- 2019-06-20 EP EP24176671.6A patent/EP4424712A3/en active Pending
- 2019-06-20 SG SG11202012137UA patent/SG11202012137UA/en unknown
- 2019-06-20 US US16/447,067 patent/US11254752B2/en active Active
- 2019-06-20 CA CA3103887A patent/CA3103887A1/en active Pending
- 2019-06-20 KR KR1020217000649A patent/KR102870971B1/ko active Active
- 2019-06-20 BR BR112020025476-2A patent/BR112020025476A2/pt unknown
- 2019-06-20 MA MA52962A patent/MA52962B1/fr unknown
- 2019-06-20 RS RS20240959A patent/RS65886B1/sr unknown
- 2019-06-20 AU AU2019290170A patent/AU2019290170B2/en active Active
- 2019-06-20 MX MX2020013905A patent/MX2020013905A/es unknown
- 2019-06-20 DK DK19739472.9T patent/DK3810281T3/da active
- 2019-06-20 PT PT197394729T patent/PT3810281T/pt unknown
- 2019-06-20 EA EA202190088A patent/EA202190088A1/ru unknown
- 2019-06-20 IL IL279251A patent/IL279251B2/en unknown
- 2019-06-20 JP JP2020570938A patent/JP7403480B2/ja active Active
- 2019-06-20 CN CN201980040564.9A patent/CN112312970B/zh active Active
- 2019-06-20 MY MYPI2020006505A patent/MY202134A/en unknown
- 2019-06-20 PL PL19739472.9T patent/PL3810281T3/pl unknown
- 2019-06-20 WO PCT/US2019/038163 patent/WO2019246356A1/en not_active Ceased
- 2019-06-20 HU HUE19739472A patent/HUE067985T2/hu unknown
- 2019-06-20 EP EP19739472.9A patent/EP3810281B1/en active Active
- 2019-06-20 FI FIEP19739472.9T patent/FI3810281T3/fi active
-
2020
- 2020-12-07 ZA ZA2020/07599A patent/ZA202007599B/en unknown
- 2020-12-10 PH PH12020552115A patent/PH12020552115A1/en unknown
- 2020-12-16 MX MX2025008444A patent/MX2025008444A/es unknown
- 2020-12-16 CL CL2020003256A patent/CL2020003256A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021528423A5 (https=) | ||
| JP2022050618A5 (https=) | ||
| IL313952A (en) | Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment | |
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| FI3932951T3 (fi) | Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria | |
| JP2019515008A5 (https=) | ||
| JP2022078265A5 (https=) | ||
| IL321717A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
| JP2020508317A5 (https=) | ||
| JP2019519499A5 (https=) | ||
| JP2022532490A5 (https=) | ||
| JP2021527431A5 (https=) | ||
| CN108602889A (zh) | 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体 | |
| JP2023505218A5 (https=) | ||
| JP2015500822A5 (https=) | ||
| JP2022512851A5 (https=) | ||
| TW202320827A (zh) | 用於治療癌症之檢查點抑制劑和溶瘤病毒的組合 | |
| JP2023519807A5 (https=) | ||
| JP2025134086A (ja) | 関節リウマチを有する対象における疼痛を治療するための組成物および方法 | |
| JP2025509567A5 (https=) | ||
| JP2025502061A5 (https=) | ||
| JP2021518348A5 (https=) | ||
| TW202034925A (zh) | Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途 | |
| CN117693350A (zh) | 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合 | |
| JP2024542879A5 (https=) |